1. Home
  2. KWR vs PHVS Comparison

KWR vs PHVS Comparison

Compare KWR & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

KWR

Quaker Houghton

HOLD

Current Price

$155.66

Market Cap

2.7B

Sector

Industrials

ML Signal

HOLD

Logo Pharvaris N.V.

PHVS

Pharvaris N.V.

HOLD

Current Price

$31.42

Market Cap

2.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KWR
PHVS
Founded
1918
2015
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Major Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.7B
2.4B
IPO Year
1994
2020

Fundamental Metrics

Financial Performance
Metric
KWR
PHVS
Price
$155.66
$31.42
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
7
14
Target Price
★ $193.14
$57.58
AVG Volume (30 Days)
98.2K
★ 624.5K
Earning Date
10-29-2026
11-11-2026
Dividend Yield
★ 1.35%
N/A
EPS Growth
N/A
★ N/A
EPS
★ 2.68
N/A
Revenue
★ $1,888,634,000.00
N/A
Revenue This Year
$7.73
N/A
Revenue Next Year
$4.53
N/A
P/E Ratio
$58.41
★ N/A
Revenue Growth
★ 2.66
N/A
52 Week Low
$112.18
$21.02
52 Week High
$183.01
$43.25

Technical Indicators

Market Signals
Indicator
KWR
PHVS
Relative Strength Index (RSI) 44.16 48.58
Support Level $153.07 $27.80
Resistance Level $163.12 $31.49
Average True Range (ATR) 3.58 1.40
MACD -0.18 0.25
Stochastic Oscillator 35.45 81.70

Price Performance

Historical Comparison
KWR
PHVS

About KWR Quaker Houghton

Quaker Houghton manufactures and sells a variety of industrial process fluids. The company's product portfolio includes metal removal fluids, cleaning fluids, corrosion inhibitors, metal drawing and forming fluids, die-cast mold releases, heat treatment and quenchants, metal forging fluids, hydraulic fluids, specialty greases, offshore sub-sea energy control fluids, rolling lubricants, rod and wire drawing fluids, and surface treatment chemicals. The company's geographic segments include the Americas, EMEA, and Asia/Pacific. The majority of the company's revenue is earned from the Americas.

About PHVS Pharvaris N.V.

Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.

Share on Social Networks: